GlaxoSmithKline’s (GSK) “Neutral” Rating Reiterated at JPMorgan Chase & Co.

GlaxoSmithKline (NYSE:GSK)‘s stock had its “neutral” rating reiterated by JPMorgan Chase & Co. in a report released on Monday.

Several other equities research analysts have also commented on GSK. Zacks Investment Research lowered GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Wednesday, January 17th. ValuEngine lowered GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Sunday, December 31st. UBS Group restated a “buy” rating on shares of GlaxoSmithKline in a research report on Monday, January 15th. Barclays upgraded GlaxoSmithKline from an “equal weight” rating to an “overweight” rating in a research report on Tuesday, January 16th. Finally, Investec lowered GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Monday, November 6th. Three analysts have rated the stock with a sell rating, ten have issued a hold rating and six have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $38.57.

Shares of GlaxoSmithKline (NYSE:GSK) opened at $38.51 on Monday. The company has a debt-to-equity ratio of 2.96, a current ratio of 0.64 and a quick ratio of 0.44. GlaxoSmithKline has a 52-week low of $34.52 and a 52-week high of $44.53. The company has a market capitalization of $96,779.15, a P/E ratio of 31.55, a price-to-earnings-growth ratio of 2.42 and a beta of 0.98.

In other GlaxoSmithKline news, major shareholder Plc Glaxosmithkline bought 428,571 shares of GlaxoSmithKline stock in a transaction dated Monday, November 6th. The stock was acquired at an average cost of $14.00 per share, with a total value of $5,999,994.00. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 10.00% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. Commerzbank Aktiengesellschaft FI raised its stake in shares of GlaxoSmithKline by 687.2% during the 4th quarter. Commerzbank Aktiengesellschaft FI now owns 168,346 shares of the pharmaceutical company’s stock worth $5,971,000 after buying an additional 146,960 shares during the period. Moloney Securities Asset Management LLC raised its stake in shares of GlaxoSmithKline by 15.1% during the 4th quarter. Moloney Securities Asset Management LLC now owns 30,960 shares of the pharmaceutical company’s stock worth $1,098,000 after buying an additional 4,051 shares during the period. Hoertkorn Richard Charles raised its stake in GlaxoSmithKline by 4.5% in the 4th quarter. Hoertkorn Richard Charles now owns 48,075 shares of the pharmaceutical company’s stock valued at $1,705,000 after purchasing an additional 2,050 shares during the last quarter. Founders Financial Securities LLC acquired a new position in GlaxoSmithKline in the 4th quarter valued at $645,000. Finally, Kahn Brothers Group Inc. DE raised its stake in GlaxoSmithKline by 11.6% in the 4th quarter. Kahn Brothers Group Inc. DE now owns 1,139,163 shares of the pharmaceutical company’s stock valued at $40,406,000 after purchasing an additional 118,028 shares during the last quarter. 9.70% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “GlaxoSmithKline’s (GSK) “Neutral” Rating Reiterated at JPMorgan Chase & Co.” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://www.americanbankingnews.com/2018/01/29/glaxosmithklines-gsk-neutral-rating-reiterated-at-jpmorgan-chase-co.html.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply